ImmunoGen Announces Conference Call to Discuss Its 2020 Operating Results

Rhea-AI Summary

ImmunoGen Inc. (Nasdaq: IMGN) is set to host a conference call on February 12, 2021, at 8:00 a.m. ET to discuss its 2020 operating results and provide a business update. Interested parties can join the call by dialing (877) 621-5803, with the conference ID 1666147, or access it through the company's website. ImmunoGen focuses on developing next-generation antibody-drug conjugates (ADCs) aimed at improving cancer treatment outcomes by offering therapies with enhanced anti-tumor activity.

Positive

• ImmunoGen is developing next-generation ADCs targeting improved cancer treatment outcomes.
• The company's focus on enhancing anti-tumor activity and tolerability profiles supports its mission to provide more good days for cancer patients.

Negative

• None.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 12, 2021 to discuss its 2020 operating results. Management will also provide a brief update on the business.

Conference Call Information

To access the live call by phone, dial (877) 621-5803; the conference ID is 1666147. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the webcast, a replay of the call will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210129005034/en/

FAQ

When will ImmunoGen discuss its 2020 operating results?

ImmunoGen will host a conference call on February 12, 2021, at 8:00 a.m. ET to discuss its 2020 operating results.

How can I listen to the ImmunoGen conference call?

You can listen to the ImmunoGen conference call by dialing (877) 621-5803, using conference ID 1666147, or by accessing the call through the company's website.

What is ImmunoGen's focus in cancer treatment?

ImmunoGen is focused on developing next-generation antibody-drug conjugates (ADCs) to enhance cancer treatment outcomes.